-
Signature
-
/s/ Daniel Hoeft, attorney-in-fact for Walter S. Woltosz and Virginia E. Woltosz
-
Issuer symbol
-
SLP
-
Transactions as of
-
02 Jun 2025
-
Transactions value $
-
$-543,074
-
Form type
-
4
-
Filing time
-
03 Jun 2025, 16:57:16 UTC
Reporting Owners (2)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| WOLTOSZ WALTER S |
Director, 10%+ Owner |
800 PARK OFFICES DRIVE, SUITE 401, RESEARCH TRIANGLE PARK |
/s/ Daniel Hoeft, attorney-in-fact for Walter S. Woltosz and Virginia E. Woltosz |
03 Jun 2025 |
0001222526 |
| WOLTOSZ VIRGINIA E |
10%+ Owner |
800 PARK OFFICES DRIVE, SUITE 401, RESEARCH TRIANGLE PARK |
/s/ Daniel Hoeft, attorney-in-fact for Walter S. Woltosz and Virginia E. Woltosz |
03 Jun 2025 |
0001222527 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
SLP |
Common Stock |
Sale |
$-414,160 |
-15,500 |
-0.46% |
$26.72 |
3,328,657 |
02 Jun 2025 |
Direct |
F1, F2, F3 |
| transaction |
SLP |
Common Stock |
Sale |
$-74,817 |
-2,700 |
-0.08% |
$27.71 |
3,325,957 |
02 Jun 2025 |
Direct |
F1, F2, F4 |
| transaction |
SLP |
Common Stock |
Sale |
$-20,391 |
-700 |
-0.02% |
$29.13 |
3,325,257 |
02 Jun 2025 |
Direct |
F1, F2, F5 |
| transaction |
SLP |
Common Stock |
Sale |
$-30,570 |
-1,000 |
-0.03% |
$30.57 |
3,324,257 |
02 Jun 2025 |
Direct |
F1, F2, F6 |
| transaction |
SLP |
Common Stock |
Sale |
$-3,136 |
-100 |
-0% |
$31.36 |
3,324,157 |
02 Jun 2025 |
Direct |
F1, F2, F7 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: